

**ORION PHARMA LIMITED AND ITS SUBSIDIARIES  
FINANCIAL STATEMENTS (UNAUDITED)  
AS ON 30TH SEPTEMBER 2014 (THIRD QUARTER)**

**ORION PHARMA LIMITED**  
**AND ITS SUBSIDIARIES**  
**Consolidated Statement of Financial Position (Unaudited)**  
**As at 30 September, 2014**

	Amount In BDT	
	30-Sep-14	31-Dec-13
<b>Assets</b>		
<b>Non-Current Assets</b>	<b>21,605,335,417</b>	<b>21,767,428,980</b>
Property, Plant and Equipment	14,869,820,368	15,325,310,033
Construction Work in Progress	1,179,685,758	944,048,239
Investment in Associates	3,008,733,846	2,838,596,893
Intangible Assets	2,635,738	2,635,738
Other Investments	2,544,459,708	2,656,838,077
<b>Current Assets</b>	<b>4,397,235,723</b>	<b>3,986,771,980</b>
Inventories	498,779,620	454,601,408
Trade and Other Receivables	2,073,778,923	1,940,165,721
Advances, Deposits & Prepayments	1,230,467,267	381,971,663
Fixed Deposit with Banks	517,465,568	573,432,549
Cash and Cash Equivalents	76,744,345	636,600,639
<b>Total Assets</b>	<b>26,002,571,140</b>	<b>25,754,200,960</b>
<b>Equity and Liabilities</b>		
<b>Shareholders' Equity</b>	<b>15,835,306,077</b>	<b>15,264,068,667</b>
Share Capital	2,340,000,000	2,340,000,000
Share Premium	8,016,892,026	8,016,892,026
Reserves	2,179,583,060	2,137,082,854
Retained Earnings	3,298,830,991	2,770,093,787
Non - Controlling Interest	743,960,805	611,405,042
<b>Total Equity</b>	<b>16,579,266,882</b>	<b>15,875,473,709</b>
<b>Non-Current Liabilities</b>	<b>3,293,142,314</b>	<b>4,852,126,310</b>
Redeemable Preference Share	1,000,000,000	1,000,000,000
Non-current portion of secured term loan	2,083,487,017	3,642,348,057
Provision for Decommissioning of Assets	118,795,044	104,736,755
Employee Benefits Provision	17,027,652	18,931,086
Deferred Tax Liability	73,832,601	86,110,412
<b>Current Liabilities</b>	<b>6,130,161,943</b>	<b>5,026,600,941</b>
Short Term Loan	1,471,588,361	529,466,134
Current portion of secured term loans	2,833,057,812	2,694,825,318
Trade and Other Payable	208,100,711	613,542,427
Accrued Expenses	1,617,415,059	1,188,767,062
<b>Total equity &amp; Liabilities</b>	<b>26,002,571,140</b>	<b>25,754,200,960</b>
<b>Number of Shares used to compute NAV</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Asset Value (NAV) Including Revaluation Surplus</b>	<b>67.67</b>	<b>65.23</b>
<b>Net Asset Value (NAV) Excluding Revaluation Surplus</b>	<b>59.21</b>	<b>55.82</b>

Sd/-  
Managing Director

Sd/-  
Chief Financial Officer

**ORION PHARMA LIMITED**  
**Statement of Financial Position (Unaudited)**  
**As at 30 September, 2014**

	Amount In BDT	
	30-Sep-14	31-Dec-13
<b>Assets</b>		
<b>Non-Current Assets</b>	<b>12,027,343,017</b>	<b>11,777,639,942</b>
Property, Plant and Equipment	4,270,208,037	4,295,619,911
Construction Work in Progress	1,128,218,100	892,580,581
Investment in Subsidiaries	1,175,600,000	1,175,600,000
Investment in Associates	2,909,378,293	2,757,522,493
Other Investments	2,543,938,588	2,656,316,957
<b>Current Assets</b>	<b>3,687,309,866</b>	<b>2,836,921,684</b>
Inventories	341,677,833	301,314,591
Trade and Other Receivables	1,710,061,496	1,290,368,671
Advances, Deposits & Prepayments	1,046,816,024	218,843,049
Fixed Deposit with Banks	517,465,568	573,432,549
Cash and Cash Equivalents	71,288,945	452,962,824
<b>Total Assets</b>	<b>15,714,652,883</b>	<b>14,614,561,626</b>
<b>Equity and Liabilities</b>		
<b>Shareholders' Equity</b>	<b>13,310,651,906</b>	<b>13,227,525,217</b>
Share Capital	2,340,000,000	2,340,000,000
Share Premium	8,016,892,026	8,016,892,026
Reserves	1,733,973,133	1,698,087,396
Retained Earnings	1,219,786,747	1,172,545,795
<b>Non-current Liabilities</b>	<b>90,860,253</b>	<b>105,041,497</b>
Employee Benefit Provision	17,027,652	18,931,086
Deferred Tax Liability	73,832,601	86,110,412
<b>Current Liabilities</b>	<b>2,313,140,724</b>	<b>1,281,994,912</b>
Short Term Loans	1,471,588,361	529,466,134
Trade & Other Payables	146,786,966	167,253,209
Accrued Expenses	694,765,397	585,275,569
<b>Total equity &amp; Liabilities</b>	<b>15,714,652,883</b>	<b>14,614,561,626</b>
<b>Number of Shares used to compute NAV</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Net Asset Value (NAV) Including Revaluation Surplus</b>	<b>56.88</b>	<b>56.53</b>
<b>Net Asset Value (NAV) Excluding Revaluation Surplus</b>	<b>50.45</b>	<b>49.76</b>

Sd/-  
Managing Director

Sd/-  
Chief Financial Officer

**ORION PHARMA LIMITED  
AND ITS SUBSIDIARIES**

**Consolidated Statement of Comprehensive Income ( Unaudited)**

**For the 3rd quarter ended 30 September, 2014**

	Amount In BDT			
	1 January to 30 September 2014	1 January to 30 September 2013	1 July to 30 September 2014	1 July to 30 September 2013
<b>Revenue from Net Sales</b>	8,556,639,979	8,224,415,767	2,937,297,920	3,192,524,810
Cost of Goods Sold	(604,826,057)	(572,189,454)	(191,896,144)	(206,620,284)
Cost of Power Generation	(5,760,486,257)	(5,255,211,678)	(2,126,702,881)	(2,213,947,914)
<b>Gross Profit</b>	<b>2,191,327,665</b>	<b>2,397,014,635</b>	<b>618,698,895</b>	<b>771,956,612</b>
<b>Operating Expenses</b>	<b>(520,263,646)</b>	<b>(498,001,015)</b>	<b>(153,814,758)</b>	<b>(163,723,881)</b>
General & Administrative Expenses	(137,333,722)	(127,609,680)	(17,672,898)	(38,873,607)
Selling & Distribution Expenses	(382,929,924)	(370,391,335)	(136,141,860)	(124,850,274)
<b>Profit from Operation</b>	<b>1,671,064,019</b>	<b>1,899,013,620</b>	<b>464,884,137</b>	<b>608,232,731</b>
Financial Expenses	(793,717,585)	(1,003,049,788)	(259,173,016)	(329,272,251)
Interest & Other Income	117,986,087	112,720,568	2,584,693	8,302,383
<b>Net Profit from Operation</b>	<b>995,332,521</b>	<b>1,008,684,400</b>	<b>208,295,814</b>	<b>287,262,863</b>
Workers Profit Participation Fund	(17,027,652)	(16,440,067)	(528,182)	(2,982,288)
<b>Net Profit before Tax</b>	<b>978,304,869</b>	<b>992,244,333</b>	<b>207,767,632</b>	<b>284,280,575</b>
<b>Income Tax</b>	<b>(62,103,783)</b>	<b>(94,227,929)</b>	<b>3,692,304</b>	<b>(12,025,185)</b>
Current Tax Expenses/Income	(69,810,655)	(95,543,241)	(2,522,955)	(17,421,947)
Deferred Tax Expenses	7,706,872	1,315,312	6,215,259	5,396,762
<b>Net Profit after Tax</b>	<b>916,201,086</b>	<b>898,016,404</b>	<b>211,459,936</b>	<b>272,255,390</b>
Share of Profit from Associate	107,293,540	8,543,851	9,508,183	2,308,579
<b>Net Profit</b>	<b>1,023,494,626</b>	<b>906,560,255</b>	<b>220,968,119</b>	<b>274,563,969</b>
Less: Non Controlling Interest (share of operating profit)	(134,513,328)	(134,392,317)	(41,629,663)	(44,702,034)
<b>Net Profit after Tax before Other Comprehensive Income</b>	<b>888,981,298</b>	<b>772,167,938</b>	<b>179,338,456</b>	<b>229,861,935</b>
<b>Add: Other Comprehensive Income</b>	<b>72,407,411</b>	<b>51,615,600</b>	<b>72,365,583</b>	<b>84,989,157</b>
Fair Value Gain of Marketable Securities	3,821,631	67,854,975	7,439,163	70,516,559
Share of Other Comprehensive Income	(4,747,650)	(20,003,918)	(23,941,710)	5,969,944
Fair Value Gain on Investment in Associates	73,333,430	3,764,543	88,868,130	8,502,654
<b>Total Comprehensive Income Attributable to Ordinary Share Holder</b>	<b>961,388,709</b>	<b>823,783,538</b>	<b>251,704,039</b>	<b>314,851,092</b>
<b>Number of Shares used to compute EPS</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Basic Earning Per Share (EPS)</b>	<b>3.80</b>	<b>3.30</b>	<b>0.77</b>	<b>0.98</b>

Sd/-  
Managing Director

Sd/-  
Chief Financial Officer

**ORION PHARMA LIMITED**  
**Statement of Comprehensive Income ( Unaudited)**  
**For the 3rd quarter ended 30 September, 2014**

	Amount In BDT			
	1 January to 30 September 2014	1 January to 30 September 2013	1 July to 30 September 2014	1 July to 30 September 2013
Revenue from Net Sales	1,416,971,834	1,342,576,962	371,617,798	417,868,297
Cost of Goods Sold	(604,826,057)	(572,189,454)	(191,896,144)	(206,620,284)
<b>Gross Profit</b>	<b>812,145,777</b>	<b>770,387,508</b>	<b>179,721,654</b>	<b>211,248,013</b>
<b>Operating Expenses</b>	<b>(520,263,646)</b>	<b>(497,558,983)</b>	<b>(153,814,758)</b>	<b>(163,360,482)</b>
General & Administrative Expenses	(137,333,722)	(127,167,648)	(17,672,898)	(38,510,208)
Selling & Distribution Expenses	(382,929,924)	(370,391,335)	(136,141,860)	(124,850,274)
<b>Profit from Operation</b>	<b>291,882,131</b>	<b>272,828,525</b>	<b>25,906,896</b>	<b>47,887,531</b>
Financial Expenses	(52,287,525)	(57,804,009)	(17,399,762)	(11,061,652)
Interest & Other Income	117,986,087	112,716,891	2,584,693	8,302,170
<b>Net Profit from Operation</b>	<b>357,580,693</b>	<b>327,741,407</b>	<b>11,091,827</b>	<b>45,128,049</b>
Workers Profit Participation Fund	(17,027,652)	(15,606,734)	(528,182)	(2,148,955)
<b>Net Profit before Tax</b>	<b>340,553,041</b>	<b>312,134,673</b>	<b>10,563,645</b>	<b>42,979,094</b>
<b>Income Tax</b>	<b>(62,103,783)</b>	<b>(89,684,498)</b>	<b>3,692,304</b>	<b>(8,121,754)</b>
Current Tax Expenses	(69,810,655)	(90,999,810)	(2,522,955)	(13,518,516)
Deferred Tax Expenses/Income	7,706,872	1,315,312	6,215,259	5,396,762
<b>Net Profit after Tax</b>	<b>278,449,258</b>	<b>222,450,175</b>	<b>14,255,949</b>	<b>34,857,340</b>
Share of Profit from Associate	103,170,100	6,884,370	11,400,583	1,592,496
<b>Net Profit after Tax before Other Comprehensive Income</b>	<b>381,619,358</b>	<b>229,334,545</b>	<b>25,656,532</b>	<b>36,449,836</b>
<b>Add: Other Comprehensive Income</b>	<b>52,507,331</b>	<b>55,267,080</b>	<b>52,226,463</b>	<b>74,576,794</b>
Fair Value Gain of Marketable Securities	3,821,631	67,854,975	7,439,163	70,516,559
Fair Value Gain on Investment in Associate	48,752,150	(13,799,029)	34,000,250	4,060,235
Share of Other Comprehensive Income	(66,450)	1,211,134	10,787,050	5,865,269
<b>Total Comprehensive Income attribute to Ordinary Share Holders</b>	<b>434,126,689</b>	<b>284,601,625</b>	<b>77,882,995</b>	<b>111,026,630</b>
<b>Number of Shares used to compute EPS</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Basic Earning Per Share (EPS)</b>	<b>1.63</b>	<b>0.98</b>	<b>0.11</b>	<b>0.16</b>

Sd/-  
Managing Director

Sd/-  
Chief Financial Officer

**ORION PHARMA LIMITED  
AND ITS SUBSIDIARIES**

Consolidated Statement of Changes in Equity (Unaudited)  
For the 3rd quarter ended 30 September, 2014

Amount in BDT

Particulars	Ordinary Share Capital	Share Premium	Retained Earnings (Restated)	Reserves	Total
<b>Balance at 01 January 2013</b>	1,550,000,000	6,547,500,000	2,008,217,947	2,669,095,500	12,774,813,447
Net Profit after Tax	-	-	772,167,938	-	772,167,938
Share Issued	400,000,000	-	-	-	400,000,000
Share premium Received	-	2,000,000,000	-	-	2,000,000,000
Tax on Share premium Received	-	(60,000,000)	-	-	(60,000,000)
Cash Dividend for the year 2012	-	-	(390,000,000)	-	(390,000,000)
Stock Dividend for the year 2012	390,000,000	(390,000,000)	-	-	-
Fair Value Gain on Investment in Associates	-	-	-	(20,003,918)	(20,003,918)
Fair Value Loss on Marketable Securities	-	-	-	67,854,975	67,854,975
Share of Other Comprehensive Income	-	-	-	3,764,543	3,764,543
Perior Year Adjustment with Tax Provision	-	-	-	-	-
Depreciation on Revaluation Surplus	-	-	31,022,892	(31,022,892)	-
<b>Balance at 30 September 2013</b>	<b>2,340,000,000</b>	<b>8,097,500,000</b>	<b>2,421,408,777</b>	<b>2,689,688,208</b>	<b>15,548,596,985</b>
<b>Balance at 01 January 2014</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>2,770,093,787</b>	<b>2,137,082,854</b>	<b>15,264,068,667</b>
Net Profit after Tax	-	-	888,981,298	-	888,981,298
Cash Dividend for the year 2013	-	-	(351,000,000)	-	(351,000,000)
Fair Value Gain/(Loss) on Investment in Associat	-	-	-	73,333,430	73,333,430
Perior Year Adjustment	-	-	(39,151,299)	-	(39,151,299)
Fair Value gain/(loss) on Marketable Securities	-	-	-	3,821,631	3,821,631
Share of Other Comprehensive Income	-	-	-	(4,747,650)	(4,747,650)
Depreciation on Revaluation Surplus	-	-	29,907,204	(29,907,204)	-
<b>Balance at 30 September 2014</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>3,298,830,991</b>	<b>2,179,583,060</b>	<b>15,835,306,077</b>

Sd/-  
Managing Director

Sd/-  
Chief Financial Officer

## ORION PHARMA LIMITED

### Statement of Changes in Equity (Unaudited) For the 3rd quarter ended 30 September, 2014

Particulars	Amount in BDT				
	Ordinary Share Capital	Share Premium	Retained Earnings	Reserves	Total
<b>Balance at 01 January 2013</b>	1,550,000,000	6,547,500,000	1,162,995,794	1,759,515,204	11,020,010,998
Net Profit after Tax	-	-	229,334,545	-	229,334,545
Share Issued	400,000,000	-	-	-	400,000,000
Share premium Received	-	2,000,000,000	-	-	2,000,000,000
Tax on Share premium Received	-	(60,000,000)	-	-	(60,000,000)
Cash Dividend for the year 2012	-	-	(390,000,000)	-	(390,000,000)
Stock Dividend for the year 2012	390,000,000	(390,000,000)	-	-	-
Fair Value Gain on Investment in Associates	-	-	-	(13,799,029)	(13,799,029)
Fair Value Loss on Marketable Securities	-	-	-	67,854,975	67,854,975
Share of Other Comprehensive Income	-	-	-	1,211,134	1,211,134
Depreciation on Revaluation Surplus	-	-	12,598,441	(12,598,441)	-
<b>Balance at 30 September 2013</b>	<b>2,340,000,000</b>	<b>8,097,500,000</b>	<b>1,014,928,780</b>	<b>1,802,183,843</b>	<b>13,254,612,623</b>
<b>Balance at 01 January 2014</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,172,545,795</b>	<b>1,698,087,396</b>	<b>13,227,525,217</b>
Net Profit after Tax	-	-	381,619,358	-	381,619,358
Cash Dividend for the year 2013	-	-	(351,000,000)	-	(351,000,000)
Fair Value Gain/(Loss) on Investment in Associates	-	-	-	48,752,150	48,752,150
Fair Value (Loss)/Gain on Marketable Securities	-	-	-	3,821,631	3,821,631
Share of Other Comprehensive Income	-	-	-	(66,450)	(66,450)
Depreciation on Revaluation Surplus	-	-	16,621,593	(16,621,593)	-
<b>Balance at 30 September 2014</b>	<b>2,340,000,000</b>	<b>8,016,892,026</b>	<b>1,219,786,747</b>	<b>1,733,973,133</b>	<b>13,310,651,906</b>

Sd/-  
Managing Director

Sd/-  
Chief Financial Officer

**ORION PHARMA LIMITED**  
**AND ITS SUBSIDIARIES**  
**Consolidated Statement of Cash Flows ( Unaudited)**  
**For the 3rd quarter ended 30 September, 2014**

	Amount In BDT	
	1 January to 30 September 2014	1 January to 30 September 2013
<b>A. Cash Flows from Operating Activities :</b>		
Cash Received from Customers	8,871,923,709	7,662,879,531
Cash paid to Suppliers	(5,900,897,438)	(5,448,544,979)
Cash Payment for Operating Expenses	(765,944,539)	(409,357,502)
<b>Cash Generated from Operation</b>	<b>2,205,081,732</b>	<b>1,804,977,050</b>
Cash Payment for Income Tax	(228,091,701)	(251,598,205)
<b>Net Cash Generated/(Used) from Operating Activities</b>	<b>1,976,990,031</b>	<b>1,553,378,845</b>
<b>B. Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(125,860,595)	(428,958,884)
Capital Work in Progress	(235,637,519)	(149,633,612)
Investment in Subsidiaries, Associate & Securities	(236,052,334)	(590,996,835)
Investment in FDR	55,966,981	(100,000,000)
Interest, Dividend & Other Income	117,986,087	80,927,297
<b>Net Cash Received/(Used) in Investing Activities</b>	<b>(423,597,379)</b>	<b>(1,188,662,034)</b>
<b>C. Cash Flows from Financing Activities :</b>		
Long Term Loan Received / (Repaid)	(1,420,628,546)	(823,157,182)
Short Term Loan Received / (Repaid)	293,958,575	(191,815,763)
Share Capital Received	-	400,000,000
Share Premium Received	-	1,940,000,000
Financial expenses paid	(894,942,114)	(988,076,282)
Dividend paid	(91,636,862)	(375,131,670)
<b>Net Cash Received/(Used) in Financing Activities</b>	<b>(2,113,248,947)</b>	<b>(38,180,897)</b>
<b>Net Increase/(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(559,856,295)</b>	<b>326,535,914</b>
Cash & Cash Equivalents at the beginning of the year	636,600,639	350,001,800
<b>Cash &amp; Cash Equivalents at the end of the year</b>	<b>76,744,345</b>	<b>676,537,714</b>
<b>Number of Shares used to compute NOCFPS</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Operating Cash Flow Per Share</b>	<b>8.45</b>	<b>6.64</b>

Sd/-  
Managing Director

Sd/-  
Chief Financial Officer



**ORION PHARMA LIMITED**  
**Statement of Cash Flows ( Unaudited)**  
**For the 3rd quarter ended 30 September, 2014**

	Amount In BDT	
	1 January to 30 September 2014	1 January to 30 September 2013
<b>A. Cash Flows from Operating Activities :</b>		
Cash Received from Customers	1,235,771,062	1,335,767,063
Cash paid to Suppliers	(625,292,300)	(514,355,899)
Cash Payment for Operating Expenses	(765,944,539)	(674,161,724)
<b>Cash Generated from Operation</b>	<b>(155,465,777)</b>	<b>147,249,440</b>
Cash Payment for Income Tax	(228,091,701)	(251,535,986)
<b>Net Cash Generated/(Used) from Operating Activities</b>	<b>(383,557,478)</b>	<b>(104,286,546)</b>
<b>B. Cash Flows from Investing Activities :</b>		
Acquisition of Property, Plant & Equipment	(98,577,456)	(366,850,761)
Capital Work in Progress	(235,637,519)	(129,756,998)
Investment in Subsidiaries, Associate, Securities & Others	(236,052,334)	(532,175,895)
Investment in FDR	55,966,981	(100,000,000)
Interest, Dividend & Other Income	117,986,087	7,642,157
Other investment income	-	73,530,756
<b>Net Cash Received/(Used) in Investing Activities</b>	<b>(396,314,241)</b>	<b>(1,047,610,741)</b>
<b>C. Cash Flows from Financing Activities :</b>		
Short Term Loan Received / (Repaid)	542,122,227	(168,085,625)
Interest Paid	(52,287,525)	(54,879,864)
Cash dividend paid	(91,636,862)	(375,131,670)
Share Capital Received	-	400,000,000
Share Premium Received	-	1,940,000,000
<b>Net Cash Received/(Used) in Financing Activities</b>	<b>398,197,840</b>	<b>1,741,902,841</b>
<b>Net Increase /(Decrease) in Cash &amp; Cash Equivalents (A+B+C)</b>	<b>(381,673,879)</b>	<b>590,005,554</b>
Cash & Cash Equivalents at the beginning of the year	452,962,824	39,539,774
<b>Cash &amp; Cash Equivalents at the end of the year</b>	<b>71,288,945</b>	<b>629,545,328</b>
<b>Number of Shares used to compute NOCFPS</b>	<b>234,000,000</b>	<b>234,000,000</b>
<b>Operating Cash Flow Per Share</b>	<b>(1.64)</b>	<b>(0.45)</b>

Sd/-  
**Managing Director**

Sd/-  
**Chief Financial Officer**

## Orion Pharma Limited

### Selected explanatory notes to the financial Statements as at 30 September 2014 (Third Quarter)

#### Reporting entity

Orion Pharma Limited, earlier called Orion Laboratories Limited was incorporated in 1965 as a private limited company. The Company was converted into a public limited company on July 24, 2010. The registered office of the company is at 153-154, Tejgaon I/A, Dhaka-1208, Bangladesh. The consolidated financial statements of the company as at and for the year ended 31 December 2013 comprise the company's and its subsidiaries (together referred to as the "Group" and individually as "Group entities") and the Group's interest in associates and jointly controlled entities.

The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

Orion Pharma Limited is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products including vaccines, and health-related consumer products.

#### Accounting policies and method of computations

This financial statements are consistent with those used in the annual financial statements, prepared and published for the year ended 31 December, 2013 and there have no changes in accounting policy within the interim reporting period.

#### Subsequent events

No material events occurred after the reporting date, non-disclosure of which could affect the ability of the users of the financial statements to make proper evaluation and decision.

#### Disclosure regarding acquisition of fixed assets during the period (PPE) as on 30.09.2014

During the period addition of property plant & equipment is Tk. 9,85,77,456. Details are hereunder:

SL. NO	Particulars	Addition during the period
1	Land & land development	1,409,971
2	Factory & office building	19,542,958
3	Plant & machinery	57,606,374
4	Furniture & fixtures	2,269,211
5	Office equipment	6,253,101
6	Vehicles	2,641,362
7	Laboratory equipment	8,854,479
	<b>Total</b>	<b>98,577,456</b>

Sd/-  
Managing Director

Sd/-  
Chief Financial Officer